https://news.medxy.ai/zh/clinical-insights-lipoprotein-deposition/Medxy AIzh2026-08-14T08:33:33-07:00类脂质蛋白沉积症的临床洞察：显微喉外科的疗效与长期结局 https://news.medxy.ai/ja/lipoproteinemia-clinical-findings/Medxy AIja2026-08-14T08:33:05-07:00脂質蛋白症の臨床的知見：マイクロ喉頭手術の有効性と長期転帰 https://news.medxy.ai/vi/lipoid-proteinosis-outcome/Medxy AIvi2026-08-14T08:32:45-07:00Lipoid Proteinosis: Hiệu quả và kết cục dài hạn của microlaryngosurgery https://news.medxy.ai/clinical-insights-into-lipoid-proteinosis-efficacy-and-long-term-outcomes-of-microlaryngosurgery/Medxy AIen2026-08-14T08:31:03-07:00Clinical Insights into Lipoid Proteinosis: Efficacy and Long-Term Outcomes of Microlaryngosurgery https://news.medxy.ai/zh/robotic-vs-laparoscopic-hysterectomy/Medxy AIzh2026-08-14T08:29:39-07:00用客观工具验证机器人与腹腔镜子宫切除术表现：外科卓越迈向标准化 https://news.medxy.ai/ja/robotic-laparoscopic-hysterectomy/Medxy AIja2026-08-14T08:29:24-07:00ロボット支援下・腹腔鏡下子宮摘出術の手術成績を可視化する客観的評価ツールの有用性が明らかに https://news.medxy.ai/vi/robotic-hysterectomy-tools/Medxy AIvi2026-08-14T08:29:02-07:00Nâng tầm phẫu thuật phụ khoa: Công cụ khách quan xác thực hiệu quả trong cắt tử cung hỗ trợ bằng robot và nội soi https://news.medxy.ai/advancing-surgical-excellence-an-objective-tool-validates-performance-in-robotic-and-laparoscopic-hysterectomy/Medxy AIen2026-08-14T08:27:38-07:00Advancing Surgical Excellence: An Objective Tool Validates Performance in Robotic and Laparoscopic Hysterectomy https://news.medxy.ai/zh/adult-adrenal-leukodystrophy/Medxy AIzh2026-08-14T08:25:02-07:00成人脑型肾上腺脑白质营养不良病灶进展的解析：为个体化管理提供依据 https://news.medxy.ai/vi/adrenoleukodystrophy-progress/Medxy AIvi2026-08-14T08:24:17-07:00Giải mã tiến triển tổn thương trong adrenoleukodystrophy thể não ở người lớn để định hướng quản lý cá thể hóa https://news.medxy.ai/unraveling-lesion-progression-in-adult-cerebral-adrenoleukodystrophy-to-inform-personalized-management/Medxy AIen2026-08-14T08:22:45-07:00Unraveling Lesion Progression in Adult Cerebral Adrenoleukodystrophy to Inform Personalized Management https://news.medxy.ai/zh/electrical-stimulation-pelvic-training/Medxy AIzh2026-08-14T08:21:54-07:00电刺激生物反馈联合盆底肌训练：产后盆腔器官脱垂长期疗效如何？ https://news.medxy.ai/ja/postpartum-pelvic-floor/Medxy AIja2026-08-14T08:21:26-07:00産後骨盤臓器脱に対する電気刺激バイオフィードバック併用骨盤底筋訓練の長期効果を検証する https://news.medxy.ai/vi/long-term-impact-of-electrical-stimulation-biofeedback-combined-with-pelvic-floor-muscle-training-for-postpartum-pelvic-organ-prolapse/Medxy AIvi2026-08-14T08:19:15-07:00Đánh giá tác động dài hạn của phương pháp phản hồi sinh học kết hợp kích thích điện và tập luyện cơ sàn chậu đối với tình trạng sa tạng chậu sau sinh https://news.medxy.ai/evaluating-the-long-term-impact-of-electrical-stimulation-biofeedback-combined-with-pelvic-floor-muscle-training-for-postpartum-pelvic-organ-prolapse/Medxy AIen2026-08-14T08:17:38-07:00Evaluating the Long-Term Impact of Electrical Stimulation Biofeedback Combined with Pelvic Floor Muscle Training for Postpartum Pelvic Organ Prolapse https://news.medxy.ai/zh/her2-status-reassessment/Medxy AIzh2026-08-14T08:17:08-07:00复发性宫颈癌中HER2状态再评估：动态表达对靶向治疗的临床意义 https://news.medxy.ai/ja/her2-status-cervical-cancer/Medxy AIja2026-08-14T08:16:50-07:00再発子宮頸癌における HER2 状態を再考する：動的発現が示す分子標的治療への臨床的含意 https://news.medxy.ai/vi/her2-cervical-cancer/Medxy AIvi2026-08-14T08:16:32-07:00Tình trạng HER2 ở ung thư cổ tử cung tái phát: Ý nghĩa lâm sàng của sự biến thiên biểu hiện đối với điều trị nhắm đích https://news.medxy.ai/revisiting-her2-status-in-recurrent-cervical-cancer-clinical-implications-of-dynamic-expression-for-targeted-therapy/Medxy AIen2026-08-14T08:13:19-07:00Revisiting HER2 Status in Recurrent Cervical Cancer: Clinical Implications of Dynamic Expression for Targeted Therapy https://news.medxy.ai/zh/inebilizumab-mg-study/Medxy AIzh2026-08-14T08:12:58-07:00Inebilizumab 显著降低全身型重症肌无力加重与急救治疗需求：来自 III 期 MINT 试验的启示 https://news.medxy.ai/ja/generalized-myasthenia-gravis/Medxy AIja2026-08-14T08:11:58-07:00全身型重症筋無力症の増悪とレスキュー療法を大幅に抑制：第3相MINT試験からみたイネビリズマブの意義 https://news.medxy.ai/vi/inebilizumab-efficacy-myasthenia-gravis/Medxy AIvi2026-08-14T08:11:34-07:00Inebilizumab cho thấy hiệu quả vượt trội trong giảm đợt kịch phát và nhu cầu cứu hộ ở nhược cơ toàn thân: Kết quả từ thử nghiệm pha 3 MINT https://news.medxy.ai/inebilizumab-significantly-reduces-exacerbations-and-need-for-rescue-therapy-in-generalized-myasthenia-gravis-insights-from-the-phase-3-mint-trial/Medxy AIen2026-08-14T08:08:12-07:00Inebilizumab Significantly Reduces Exacerbations and Need for Rescue Therapy in Generalized Myasthenia Gravis: Insights from the Phase 3 MINT Trial https://news.medxy.ai/zh/liver-transplant-colorectal-cancer/Medxy AIzh2026-08-14T08:06:51-07:00结直肠癌不可切除肝转移的肝移植：SECA-II研究揭示长期生存与潜在治愈价值 https://news.medxy.ai/ja/liver-transplant-colon-cancer/Medxy AIja2026-08-14T08:06:34-07:00切除不能な大腸癌肝限局転移に対する肝移植の長期生存と根治可能性：SECA-II研究からの示唆 https://news.medxy.ai/vi/liver-transplant-colorectal-cancer-2/Medxy AIvi2026-08-14T08:06:14-07:00Ghép gan cho di căn gan do ung thư đại trực tràng không thể cắt bỏ: thời gian sống lâu dài và tiềm năng khỏi bệnh từ nghiên cứu SECA-II https://news.medxy.ai/long-term-survival-and-curative-potential-of-liver-transplantation-for-nonresectable-colorectal-liver-metastases-insights-from-the-seca-ii-study/Medxy AIen2026-08-14T08:04:54-07:00Long-Term Survival and Curative Potential of Liver Transplantation for Nonresectable Colorectal Liver Metastases: Insights from the SECA-II Study https://news.medxy.ai/zh/antiplatelet-use-after-ich/Medxy AIzh2026-08-14T08:04:37-07:00ICH 后能否用抗血小板药？STATICH 试验给出的风险与获益信号 https://news.medxy.ai/ja/antiplatelet-therapy-after-ich/Medxy AIja2026-08-14T08:04:11-07:00ICH後の抗血小板療法をどう考えるか：STATICH試験が示したリスクと利益の均衡 https://news.medxy.ai/vi/antiplatelet-therapy-risk-balance/Medxy AIvi2026-08-14T08:03:49-07:00Cân bằng nguy cơ: Điều trị kháng kết tập tiểu cầu sau xuất huyết nội sọ trong thử nghiệm STATICH https://news.medxy.ai/balancing-risks-antiplatelet-therapy-after-intracerebral-haemorrhage-in-the-statich-trial/Medxy AIen2026-08-14T08:02:21-07:00Balancing Risks: Antiplatelet Therapy After Intracerebral Haemorrhage in the STATICH Trial https://news.medxy.ai/zh/military-trauma-triage/Medxy AIzh2026-08-14T08:02:00-07:00军事创伤二元分诊系统简化评估：准确性与作战可行性的平衡 https://news.medxy.ai/ja/military-trauma-triage-2/Medxy AIja2026-08-14T08:01:32-07:00軍事外傷における簡略化二択トリアージの有用性を検証する：精度と運用実現性の両立 https://news.medxy.ai/vi/military-trauma-priority-classification/Medxy AIvi2026-08-14T08:01:04-07:00Đánh giá hệ thống phân loại ưu tiên nhị phân đơn giản hóa trong chấn thương quân sự: Cân bằng giữa độ chính xác và tính khả thi trong tác chiến https://news.medxy.ai/evaluating-a-simplified-binary-triage-system-for-military-trauma-balancing-accuracy-and-operational-feasibility/Medxy AIen2026-08-14T07:59:28-07:00Evaluating a Simplified Binary Triage System for Military Trauma: Balancing Accuracy and Operational Feasibility https://news.medxy.ai/zh/lung-cancer-surgery-range/Medxy AIzh2026-08-14T07:59:02-07:00非小细胞肺癌切除范围与切缘阳性的关系：手术范围并非决定因素 https://news.medxy.ai/ja/impact-resection-nsclc/Medxy AIja2026-08-14T07:58:46-07:00非小細胞肺癌における切除範囲の影響：断端陽性は術式に左右されない https://news.medxy.ai/vi/non-small-cell-lung-cancer/Medxy AIvi2026-08-14T07:58:24-07:00Ung thư phổi không tế bào nhỏ: bờ cắt dương tính không phụ thuộc phạm vi phẫu thuật https://news.medxy.ai/resection-extent-in-non-small-cell-lung-cancer-margin-positivity-is-unrelated-to-surgical-scope/Medxy AIen2026-08-14T07:57:10-07:00Resection Extent in Non-Small Cell Lung Cancer: Margin Positivity is Unrelated to Surgical Scope https://news.medxy.ai/zh/semaglutide-on-gestational-weight-gain-and-pregnancy-outcomes-in-obese-women/Medxy AIzh2026-08-14T07:56:47-07:00超重及肥胖女性暴露于司美格鲁肽对妊娠期体重增加及妊娠结局的影响 https://news.medxy.ai/ja/semaglutide-on-gestational-weight-gain-and-pregnancy-outcomes-in-overweight-and-obese-women/Medxy AIja2026-08-14T07:56:26-07:00過体重および肥満の女性におけるセマグルチド曝露が妊娠中の体重増加と妊娠転帰に及ぼす影響 https://news.medxy.ai/vi/semaglutide-pregnancy-weight/Medxy AIvi2026-08-14T07:56:04-07:00Phơi nhiễm semaglutide ảnh hưởng thế nào đến tăng cân thai kỳ và kết cục thai kỳ ở phụ nữ thừa cân, béo phì? https://news.medxy.ai/impact-of-semaglutide-exposure-on-gestational-weight-gain-and-pregnancy-outcomes-in-overweight-and-obese-women/Medxy AIen2026-08-14T07:54:13-07:00Impact of Semaglutide Exposure on Gestational Weight Gain and Pregnancy Outcomes in Overweight and Obese Women https://news.medxy.ai/zh/crohns-disease-additives/Medxy AIzh2026-08-14T07:53:51-07:00克罗恩病中人工甜味剂与乳化剂的新发现：来自 ENIGMA 研究的生物标志物与代谢机制 https://news.medxy.ai/ja/artificial-sweeteners-and-emulsifiers-in-crohns-disease/Medxy AIja2026-08-14T07:53:33-07:00クローン病における人工甘味料と乳化剤に関する新たな知見：ENIGMA研究から得られたバイオマーカーと代謝メカニズム https://news.medxy.ai/vi/crohns-food-additives/Medxy AIvi2026-08-14T07:53:12-07:00Bệnh Crohn và phụ gia thực phẩm: phát hiện mới về chất tạo ngọt nhân tạo, chất nhũ hóa và dấu ấn sinh học từ nghiên cứu ENIGMA https://news.medxy.ai/new-insights-into-artificial-sweeteners-and-emulsifiers-in-crohns-disease-biomarkers-and-metabolic-mechanisms-from-the-enigma-study/Medxy AIen2026-08-14T07:51:50-07:00New Insights into Artificial Sweeteners and Emulsifiers in Crohn’s Disease: Biomarkers and Metabolic Mechanisms from the ENIGMA Study https://news.medxy.ai/zh/cardiovascular-kidney-metabolic-syndrome-masld-fibrosis-risk/Medxy AIzh2026-08-14T07:51:28-07:00心血管—肾脏—代谢综合征与MASLD中肝纤维化进展及肝相关事件风险 https://news.medxy.ai/ja/masld-cardiovascular-renal-metabolic-syndrome/Medxy AIja2026-08-14T07:51:07-07:00MASLDにおける心血管・腎・代謝症候群と肝線維化進行・肝関連イベントへの影響 https://news.medxy.ai/vi/cardiorenal-metabolic-syndrome/Medxy AIvi2026-08-14T07:50:35-07:00Hội chứng tim mạch-thận-chuyển hóa và tác động của nó lên tiến triển xơ hóa gan cùng các biến cố liên quan đến gan trong MASLD https://news.medxy.ai/cardiovascular-kidney-metabolic-syndrome-and-its-impact-on-liver-fibrosis-progression-and-liver-related-events-in-masld/Medxy AIen2026-08-14T07:48:59-07:00Cardiovascular-Kidney-Metabolic Syndrome and Its Impact on Liver Fibrosis Progression and Liver-Related Events in MASLD https://news.medxy.ai/zh/daromun-melanoma/Medxy AIzh2026-08-13T22:03:02-07:00新辅助瘤内 Daromun 显著改善可切除 III 期黑色素瘤预后——PIVOTAL III 期试验更新解读 https://news.medxy.ai/ja/daromun-melanoma-2/Medxy AIja2026-08-13T22:02:43-07:00切除可能な第III期メラノーマに術前病変内Daromunが有望：PIVOTAL第III相試験更新で明らかになった効果 https://news.medxy.ai/vi/adjuvant-immunotherapy-melanoma/Medxy AIvi2026-08-13T22:02:18-07:00Daromun tân bổ trợ tiêm nội tổn thương cho thấy cải thiện rõ rệt kết cục ở u hắc tố giai đoạn III có thể cắt bỏ: cập nhật từ thử nghiệm pha III PIVOTAL https://news.medxy.ai/neoadjuvant-intralesional-daromun-significantly-improves-outcomes-in-resectable-stage-iii-melanoma-insights-from-the-pivotal-phase-iii-trial-update/Medxy AIen2026-08-13T22:01:06-07:00Neoadjuvant Intralesional Daromun Significantly Improves Outcomes in Resectable Stage III Melanoma: Insights from the PIVOTAL Phase III Trial Update https://news.medxy.ai/zh/age-prognosis-glioma/Medxy AIzh2026-08-13T21:52:16-07:00分子分型低级别胶质瘤中年龄作为预后指标的再评估 https://news.medxy.ai/ja/low-grade-glioma-age-prognosis/Medxy AIja2026-08-13T21:52:00-07:00分子病理で見直す低悪性度神経膠腫の年齢と予後 https://news.medxy.ai/vi/age-prognosis-low-grade-glioma/Medxy AIvi2026-08-13T21:51:38-07:00Xem xét lại vai trò của tuổi như một dấu ấn tiên lượng trong u thần kinh đệm độ thấp được xác định về mặt phân tử https://news.medxy.ai/reevaluating-age-as-a-prognostic-marker-in-molecularly-defined-lower-grade-gliomas/Medxy AIen2026-08-13T21:50:40-07:00Reevaluating Age as a Prognostic Marker in Molecularly Defined Lower-Grade Gliomas https://news.medxy.ai/zh/thyroid-nodule-sign/Medxy AIzh2026-08-13T18:28:31-07:00甲状腺结节周边间断点状强回声灶：高度提示乳头状甲状腺癌的新型超声征象 https://news.medxy.ai/vi/peripheral-microcalcifications/Medxy AIvi2026-08-13T18:28:04-07:00Các ổ tăng âm chấm nhỏ ngoại vi không liên tục: dấu ấn siêu âm mới gợi ý mạnh ung thư biểu mô tuyến giáp thể nhú https://news.medxy.ai/discontinuous-peripheral-punctate-echogenic-foci-a-novel-ultrasound-marker-highly-suggestive-of-papillary-thyroid-carcinoma/Medxy AIen2026-08-13T18:27:23-07:00Discontinuous Peripheral Punctate Echogenic Foci: A Novel Ultrasound Marker Highly Suggestive of Papillary Thyroid Carcinoma https://news.medxy.ai/zh/heart-failure-risk-diabetes-2/Medxy AIzh2026-08-13T18:27:04-07:00新诊断糖尿病中的心力衰竭风险：胰岛素抵抗与肾功能为何如此关键 https://news.medxy.ai/ja/unveiling-heart-failure-risks-in-newly-diagnosed-diabetes-insulin-resistance-and-renal-function/Medxy AIja2026-08-13T18:26:49-07:00新規診断された糖尿病における心不全リスクの解明：インスリン抵抗性と腎機能の重要な役割 https://news.medxy.ai/vi/heart-failure-risk-diabetes/Medxy AIvi2026-08-13T18:26:32-07:00Phát hiện nguy cơ suy tim ở người mới chẩn đoán đái tháo đường: Vai trò then chốt của đề kháng insulin và chức năng thận https://news.medxy.ai/unveiling-heart-failure-risks-in-newly-diagnosed-diabetes-the-critical-role-of-insulin-resistance-and-renal-function/Medxy AIen2026-08-13T18:25:50-07:00Unveiling Heart Failure Risks in Newly Diagnosed Diabetes: The Critical Role of Insulin Resistance and Renal Function https://news.medxy.ai/zh/vosoritide-growth-rasopathy/Medxy AIzh2026-08-13T18:25:32-07:00vosoritide 在 RASopathy 及相关遗传性矮身材患儿中显示出令人鼓舞的促生长作用 https://news.medxy.ai/ja/vosoritide-shows-growth-benefits-in-children-with-rasopathies-and-related-genetic-short-stature-disorders/Medxy AIja2026-08-13T18:25:16-07:00ヴォソリチド、RASopathies（ラスオパチー）および関連する遺伝性低身長症の小児において有望な成長促進効果を示す https://news.medxy.ai/vi/vosoritide-growth-benefits/Medxy AIvi2026-08-13T18:24:58-07:00Vosoritide cho thấy lợi ích tăng trưởng đầy hứa hẹn ở trẻ mắc RASopathy và các rối loạn thấp lùn di truyền liên quan https://news.medxy.ai/vosoritide-shows-promising-growth-benefits-in-children-with-rasopathies-and-related-genetic-short-stature-disorders/Medxy AIen2026-08-13T18:23:38-07:00Vosoritide Shows Promising Growth Benefits in Children with RASopathies and Related Genetic Short Stature Disorders https://news.medxy.ai/ja/gda-hba1c-correction/Medxy AIja2026-08-13T18:23:18-07:00CGM指標とHbA1cのずれを補正するGDAC研究：糖尿病診療に向けた個別化HbA1c補正の意義 https://news.medxy.ai/vi/personalized-hba1c-adjustment/Medxy AIvi2026-08-13T18:23:02-07:00Nghiên cứu GDAC về hiệu chỉnh HbA1c cá thể hóa dựa trên glucose: Cải thiện sự phù hợp giữa chỉ số từ CGM và HbA1c ở các cá thể và nhóm chủng tộc khác nhau mắc đái tháo đường, gợi ý cho thực hành lâm sàng https://news.medxy.ai/glucose-derived-personalized-hba1c-correction-gdac-study-to-improve-alignment-between-cgm-derived-metrics-and-hba1c-in-different-individuals-and-racial-groups-with-diabetes-implications-for-clinica/Medxy AIen2026-08-13T18:21:59-07:00Glucose-Derived Personalized HbA1c Correction (GDAC) Study to Improve Alignment Between CGM-Derived Metrics and HbA1c in Different Individuals and Racial Groups With Diabetes: Implications for Clinical Practice https://news.medxy.ai/zh/dynamic-metabolic-profiling-in-chronic-heart-failure/Medxy AIzh2026-08-13T18:21:41-07:00慢性心力衰竭中的动态代谢谱分析：基于连续核磁共振（NMR）生物标志物及风险预测的启示 https://news.medxy.ai/ja/chronic-heart-failure-metabolism/Medxy AIja2026-08-13T18:21:24-07:00慢性心不全における動的代謝プロファイリング：連続NMRバイオマーカーとリスク予測から得られた知見 https://news.medxy.ai/vi/metabolic-profiling-heart-failure/Medxy AIvi2026-08-13T18:21:05-07:00Lập hồ sơ chuyển hóa động trong suy tim mạn tính: Những phát hiện từ các dấu ấn sinh học NMR theo chuỗi thời gian và dự báo nguy cơ https://news.medxy.ai/dynamic-metabolic-profiling-in-chronic-heart-failure-insights-from-serial-nmr-biomarkers-and-risk-prediction/Medxy AIen2026-08-13T18:20:12-07:00Dynamic Metabolic Profiling in Chronic Heart Failure: Insights from Serial NMR Biomarkers and Risk Prediction https://news.medxy.ai/zh/oral-anticoagulants-cognition-and-clinical-outcomes-in-atrial-fibrillation-and-alzheimers-disease/Medxy AIzh2026-08-13T18:19:56-07:00房颤与阿尔茨海默病患者中的口服抗凝药、认知功能及临床结局的关联：一项瑞典全国性研究 https://news.medxy.ai/ja/afib-alzheimers-study/Medxy AIja2026-08-13T18:19:32-07:00心房細動とアルツハイマー病における経口抗凝固薬、認知機能、臨床転帰――スウェーデン全国規模研究が示す知見 https://news.medxy.ai/vi/oral-anticoagulants-alzheimers/Medxy AIvi2026-08-13T18:19:08-07:00Thuốc chống đông đường uống, nhận thức và kết cục lâm sàng ở rung nhĩ kèm bệnh Alzheimer: Những phát hiện từ một nghiên cứu toàn quốc tại Thụy Điển https://news.medxy.ai/oral-anticoagulants-cognition-and-clinical-outcomes-in-atrial-fibrillation-and-alzheimers-disease-insights-from-a-swedish-nationwide-study/Medxy AIen2026-08-13T18:17:08-07:00Oral Anticoagulants, Cognition, and Clinical Outcomes in Atrial Fibrillation and Alzheimer’s Disease: Insights from a Swedish Nationwide Study https://news.medxy.ai/ja/transthyretin-amyloid-cardiomyopathy/Medxy AIja2026-08-13T18:16:34-07:00トランスサイレチンアミロイド心筋症の疾患進行を捉え直す――機序特異的モニタリングと治療反応評価へ https://news.medxy.ai/vi/redefining-disease-progression/Medxy AIvi2026-08-13T18:16:13-07:00Tái định nghĩa tiến triển bệnh trong bệnh cơ tim amyloid transthyretin: Hướng tới theo dõi theo cơ chế và đánh giá đáp ứng điều trị https://news.medxy.ai/rethinking-disease-progression-in-transthyretin-amyloid-cardiomyopathy-toward-mechanism-specific-monitoring-and-therapeutic-response-assessment/Medxy AIen2026-08-13T18:15:31-07:00Rethinking Disease Progression in Transthyretin Amyloid Cardiomyopathy: Toward Mechanism-Specific Monitoring and Therapeutic Response Assessment https://news.medxy.ai/zh/enzyme-assay-hba2/Medxy AIzh2026-08-13T17:57:12-07:00酶学测定 2-羟基丁酸助力血糖异常筛查：超越传统空腹指标的新进展 https://news.medxy.ai/ja/dysglycemia-screening/Medxy AIja2026-08-13T17:56:56-07:00dysglycemiaスクリーニングを前進させる：2-ヒドロキシ酪酸の酵素測定が従来の空腹時指標を超える検出能を実現 https://news.medxy.ai/vi/2-hydroxybutyrate-test/Medxy AIvi2026-08-13T17:56:07-07:00Đo 2-Hydroxybutyrate bằng xét nghiệm enzym: Bước tiến mới trong sàng lọc rối loạn đường huyết vượt ngoài xét nghiệm lúc đói https://news.medxy.ai/enzymatic-2-hydroxybutyrate-assay-a-novel-screening-tool-to-detect-dysglycemia-beyond-standard-fasting-tests/Medxy AIen2026-08-13T08:12:01-07:00Enzymatic 2-Hydroxybutyrate Assay: A Novel Screening Tool to Detect Dysglycemia Beyond Standard Fasting Tests https://news.medxy.ai/zh/fetal-cardiomyopathy/Medxy AIzh2026-08-13T08:09:32-07:00多中心北美队列揭示胎儿心肌病的预后进展与风险线索 https://news.medxy.ai/ja/fetal-cardiomyopathy-prognosis/Medxy AIja2026-08-13T08:09:01-07:00胎児心筋症の転帰と予後を読み解く：北米多施設コホートから見えた最新知見 https://news.medxy.ai/vi/fetal-cardiomyopathy-2/Medxy AIvi2026-08-13T08:07:18-07:00Bệnh cơ tim thai nhi trong kỷ nguyên hiện đại: tiến triển và những dấu ấn tiên lượng từ một đoàn hệ đa trung tâm Bắc Mỹ https://news.medxy.ai/progress-and-prognostic-insights-in-fetal-cardiomyopathy-findings-from-a-multicenter-north-american-cohort/Medxy AIen2026-08-13T08:03:35-07:00Progress and Prognostic Insights in Fetal Cardiomyopathy: Findings from a Multicenter North American Cohort https://news.medxy.ai/zh/vutrisiran-in-cardiac-structure-function-and-amyloid-burden-in-attr-cm/Medxy AIzh2026-08-13T08:02:41-07:00Vutrisiran 治疗与 ATTR-CM 患者心脏结构、功能及淀粉样蛋白负荷的心血管 MRI 变化 https://news.medxy.ai/ja/vutrisiran-attr-cm-mri/Medxy AIja2026-08-13T08:02:19-07:00Vutrisiran治療がATTR-CMの心構造・心機能・アミロイド負荷に及ぼす影響を心血管MRIで検証 https://news.medxy.ai/vi/vutrisiran-mri-amyloid/Medxy AIvi2026-08-13T08:01:43-07:00Vutrisiran và những thay đổi trên MRI tim mạch ở bệnh cơ tim amyloid transthyretin: cấu trúc, chức năng và gánh nặng amyloid https://news.medxy.ai/vutrisiran-treatment-and-cardiovascular-mri-detected-changes-in-cardiac-structure-function-and-amyloid-burden-in-attr-cm/Medxy AIen2026-08-13T07:58:51-07:00Vutrisiran Treatment and Cardiovascular MRI-Detected Changes in Cardiac Structure, Function, and Amyloid Burden in ATTR-CM https://news.medxy.ai/zh/beyond-bmi-waist-hip/Medxy AIzh2026-08-13T07:58:06-07:00超越BMI：腰围与腰臀比如何提升心血管风险预测 https://news.medxy.ai/ja/bmi-waist-hip-risk/Medxy AIja2026-08-13T07:57:43-07:00BMIだけでは不十分：ウエスト周囲径とウエスト・ヒップ比が心血管リスク予測をどう高めるか https://news.medxy.ai/vi/beyond-bmi-waist-hip-ratio/Medxy AIvi2026-08-13T07:57:16-07:00Vượt ra ngoài BMI: Vòng eo và tỷ lệ vòng eo/hông giúp dự đoán nguy cơ tim mạch chính xác hơn https://news.medxy.ai/beyond-bmi-how-waist-circumference-and-waist-to-hip-ratio-enhance-cardiovascular-risk-prediction/Medxy AIen2026-08-13T07:55:31-07:00Beyond BMI: How Waist Circumference and Waist-to-Hip Ratio Enhance Cardiovascular Risk Prediction https://news.medxy.ai/zh/myasthenia-gravis-antibody-test/Medxy AIzh2026-08-13T07:27:00-07:00重症肌无力抗体检测方法如何选？ADAM研究带来新证据 https://news.medxy.ai/ja/myasthenia-gravis-antibody-test-2/Medxy AIja2026-08-13T07:26:29-07:00重症筋無力症における抗体検査法を再考する：ADAM研究が示した知見 https://news.medxy.ai/vi/antibody-detection-myasthenia/Medxy AIvi2026-08-13T07:26:05-07:00Đánh giá các phương pháp phát hiện kháng thể trong bệnh nhược cơ: Những phát hiện từ nghiên cứu ADAM https://news.medxy.ai/evaluating-antibody-detection-methods-in-myasthenia-gravis-insights-from-the-adam-study/Medxy AIen2026-08-13T07:23:59-07:00Evaluating Antibody Detection Methods in Myasthenia Gravis: Insights from the ADAM Study https://news.medxy.ai/zh/fibroscan-liver-stiffness/Medxy AIzh2026-08-13T07:19:37-07:00Fibroscan® 肝脏硬度测量在原发性硬化性胆管炎预后评估中的价值：前瞻性 FICUS 队列研究新发现 https://news.medxy.ai/vi/liver-stiffness-prediction-2/Medxy AIvi2026-08-13T07:18:44-07:00Đo độ cứng gan có thực sự dự báo tiên lượng trong viêm đường mật xơ hóa nguyên phát? Dữ liệu từ đoàn hệ FICUS tiền cứu https://news.medxy.ai/validating-liver-stiffness-measurement-as-a-prognostic-tool-in-primary-sclerosing-cholangitis-insights-from-the-prospective-ficus-cohort/Medxy AIen2026-08-13T07:16:24-07:00Validating Liver Stiffness Measurement as a Prognostic Tool in Primary Sclerosing Cholangitis: Insights from the Prospective FICUS Cohort https://news.medxy.ai/zh/braf-v600-melanoma-survival/Medxy AIzh2026-08-13T00:09:57-07:00BRAF V600 突变晚期黑色素瘤中 Spartalizumab 联合 Dabrafenib 与 Trametinib 的长期生存获益：COMBI-I 试验启示 https://news.medxy.ai/ja/braf-v600-spartalizumab-benefit/Medxy AIja2026-08-13T00:09:32-07:00BRAF V600変異陽性進行悪性黒色腫におけるspartalizumab併用の長期生存ベネフィット：COMBI-I試験からの知見 https://news.medxy.ai/vi/spartalizumab-braf-trial/Medxy AIvi2026-08-13T00:09:09-07:00Spartalizumab kết hợp dabrafenib và trametinib mang lại lợi ích sống còn dài hạn ở u hắc tố tiến triển mang đột biến BRAF V600: Kết quả từ thử nghiệm COMBI-I https://news.medxy.ai/long-term-survival-benefit-of-spartalizumab-with-dabrafenib-and-trametinib-in-braf-v600-mutant-advanced-melanoma-insights-from-the-combi-i-trial/Medxy AIen2026-08-13T00:07:37-07:00Long-Term Survival Benefit of Spartalizumab with Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma: Insights from the COMBI-I Trial